Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of EndoChoice Holdings Inc (NYSE: GI) acted responsibly on behalf of investors’ profitability in the planned $210 million sale to Boston Scientific Corporation (NYSE: BSX).

On September 27, 2016, EndoChoice Holdings Inc (NYSE: GI) and Boston Scientific Corporation (NYSE: BSX) announced that they had entered into a merger agreement. Under the terms of the merger agreement, Boston Scientific will offer EndoChoice shareholders $8.00 per share in cash for all outstanding shares.    

Based in Alpharetta, Georgia, and founded in 2008 EndoChoice Holdings Inc is a medical device company, designing and commercializing numerous products for gastrointestinal caregivers.

The investigation is looking to uncover whether EndoChoice Holdings Inc was undervalued at the cost of the shareholders considering one analyst’s opinion of their stock is valued at $10.00 per share.

If you purchased EndoChoice Holdings Inc (NYSE: GI) prior to September 27, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185